What's Going On With Royalty Pharma Stock Wednesday?

Benzinga2025-12-31

Royalty Pharma plc (NASDAQ:RPRX) stock has gained around 53% year to date, as per data from Benzinga Pro. On Monday, Royalty Pharma acquired the final portion of PTC Therapeutics Inc.’s (NASDAQ:PTCT) ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2600559708?lang=en_US&edition=fundamental","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/31/Genetic-Research-And-Biotech-Science-Con.jpeg?optimize=medium&dpr=2&auto=webp&width=630","is_english":true,"pubTime":"2025-12-31 23:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2600559708","market":"hk","top_or_hot":-1,"title":"What's Going On With Royalty Pharma Stock Wednesday?","media":"Benzinga","content":"<div>\n<p>Royalty Pharma plc (NASDAQ:RPRX) stock has gained around 53% year to date, as per data from Benzinga Pro.\nOn Monday, Royalty Pharma acquired the final portion of PTC Therapeutics Inc.’s (NASDAQ:PTCT) ...</p>\n\n<a href=\"https://www.benzinga.com/news/health-care/25/12/49649858/whats-going-on-with-royalty-pharma-stock-wednesday\">Source Link</a>\n\n</div>\n","source":"benzinga_hot_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>What's Going On With Royalty Pharma Stock Wednesday?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhat's Going On With Royalty Pharma Stock Wednesday?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-31 23:47 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/news/health-care/25/12/49649858/whats-going-on-with-royalty-pharma-stock-wednesday><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Royalty Pharma plc (NASDAQ:RPRX) stock has gained around 53% year to date, as per data from Benzinga Pro.\nOn Monday, Royalty Pharma acquired the final portion of PTC Therapeutics Inc.’s (NASDAQ:PTCT) ...</p>\n\n<a href=\"https://www.benzinga.com/news/health-care/25/12/49649858/whats-going-on-with-royalty-pharma-stock-wednesday\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SMA","symbol_name":"Smartstop Self Storage REIT Inc","start_time":0,"source_url":"https://www.benzinga.com/news/health-care/25/12/49649858/whats-going-on-with-royalty-pharma-stock-wednesday","article_id":"2600559708","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/31/Genetic-Research-And-Biotech-Science-Con.jpeg?optimize=medium&dpr=2&auto=webp&width=630"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/news/health-care/25/12/49649858/whats-going-on-with-royalty-pharma-stock-wednesday","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2600559708","pubTimestamp":1767196020,"columns":[],"sourceInfo":{"source_id":"benzinga_hot_news","name":"Benzinga"},"weMediaInfo":null,"summary":"Royalty Pharma plc  stock has gained around 53% year to date, as per data from Benzinga Pro.On Monday, Royalty Pharma acquired the final portion of PTC Therapeutics Inc.’s  remaining royalty on Roche Holdings AG’s  Evrysdi for $240 million upfront and up to $60 million in sales-based milestones.Evrysdi, marketed by Roche, is an orally administered survival motor neuron-2  splicing modifier for the treatment of spinal muscular atrophy .Also Read: Denali Flags Minimal Delay After FDA Halts Rare Disease Trial Start. The FDA approved Evrysdi in 2020 and has treated over 21,000 patients worldwide.In 2024, Evrysdi generated sales of approximately 1.6 billion Swiss francs , representing 18% year-over-year growth at constant exchange rates, and is projected to reach 2.3 billion Swiss francs  of sales by 2030 based on analyst consensus.In March 2025, Novartis AG  shared safety and efficacy results from the Phase 3 program for investigational intrathecal onasemnogene abeparvovec  in a broad popu","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"SMA":"Smartstop Self Storage REIT Inc","NUVL":"Nuvalent, Inc.","LU0211331839.USD":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","BK4539":"次新股","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","BK4532":"文艺复兴科技持仓","BK4217":"自存仓储房地产信托","PTCT":"PTC Therapeutics Inc.","LU0234570918.USD":"高盛全球核心股票组合Acc Close","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","BK4585":"ETF&股票定投概念","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","BK4139":"生物科技","NVS":"诺华","RPRX":"Royalty Pharma plc","IE00B19Z9Z06.USD":"Legg Mason ClearBridge - US Aggressive Growth A Acc USD","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","BK4533":"AQR资本管理(全球第二大对冲基金)","LU0208291251.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) INC","LU0070302665.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) ACC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","BK4578":"CAR-T","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","IE00B19Z9P08.USD":"LEGG MASON CLEARBRIDGE US AGGRESSIVE GROWTH \"A\" (USD) INC","IE00B894F039.SGD":"Legg Mason ClearBridge - US Aggressive Growth A Acc SGD-H","BK4588":"碎股","BIIB":"渤健公司","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU0320765489.SGD":"FTIF - Franklin Mutual US Value A Acc SGD","BK4007":"制药"},"translate_title":"周三Royalty Pharma股票发生了什么？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NUVL":1,"SMA":1,"BIIB":1,"NVS":1,"RPRX":1,"PTCT":1},"content_text":"Royalty Pharma plc (NASDAQ:RPRX) stock has gained around 53% year to date, as per data from Benzinga Pro.\nOn Monday, Royalty Pharma acquired the final portion of PTC Therapeutics Inc.’s (NASDAQ:PTCT) remaining royalty on Roche Holdings AG’s (OTC:RHHBY) Evrysdi for $240 million upfront and up to $60 million in sales-based milestones.\nEvrysdi, marketed by Roche, is an orally administered survival motor neuron-2 (SMN2) splicing modifier for the treatment of spinal muscular atrophy (SMA).\nAlso Read: Denali Flags Minimal Delay After FDA Halts Rare Disease Trial Start\nThe FDA approved Evrysdi in 2020 and has treated over 21,000 patients worldwide.\nIn 2024, Evrysdi generated sales of approximately 1.6 billion Swiss francs ($1.9 billion), representing 18% year-over-year growth at constant exchange rates, and is projected to reach 2.3 billion Swiss francs ($2.9 billion) of sales by 2030 based on analyst consensus.\nRoyalty Pharma will own 100% of the tiered 8% to 16% royalty paid by Roche on worldwide net sales of Evrysdi.\nRoyalty Pharma will receive the increased royalty starting in the first quarter of 2026, based on Evrysdi product sales in the fourth quarter of 2025.\nIn September, Biogen Inc. (NASDAQ:BIIB) unveiled plans to test Spinraza in patients who’ve already been treated with Evrysdi.\nIn March 2025, Novartis AG (NYSE:NVS) shared safety and efficacy results from the Phase 3 program for investigational intrathecal onasemnogene abeparvovec (OAV101 IT) in a broad population of patients aged two to <18 years with spinal muscular atrophy (SMA).\nIn the Phase 3b STRENGTH study, treatment with OAV101 IT in patients who have discontinued treatment with Biogen’s Spinraza (nusinersen) or Evrysdi (risdiplam) demonstrated stabilization of motor function over 52 weeks of follow-up.\nIn December, Royalty Pharma acquired a pre-existing royalty interest in Nuvalent Inc.’s (NASDAQ:NUVL) neladalkib and zidesamtinib from an undisclosed third party for up to $315 million.\nNeladalkib is in development for patients with ALK mutation-positive non-small cell lung cancer (NSCLC), and zidesamtinib is in development for ROS1 mutation-positive NSCLC.\nIn November 2025, Nuvalent reported positive pivotal results for neladalkib in TKI pre-treated patients, which demonstrated durable activity and a generally well-tolerated safety profile.\nNeladalkib is also being evaluated in an ongoing Phase 3 study in TKI-naïve patients.\nZidesamtinib is currently undergoing review by the U.S. Food and Drug Administration and has an action date of September 18, 2026, for TKI pre-treated patients.\nZidesamtinib is also being assessed in an ongoing Phase 1/2 study in TKI-naïve patients.\nExisting analyst consensus projects neladalkib sales to be approximately $3.5 billion and zidesamtinib sales to be approximately $1.9 billion by 2035.\nRPRX Price Action: Royalty Pharma shares were down 0.35% at $38.85 at the time of publication on Wednesday, according to Benzinga Pro data.\nRead Next:\nImage via Shutterstock","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2600559708","isCrawlerRequest":true}